We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 19.39 | 2.07% | 957.00 | 954.85 | 990.00 | 958.13 | 926.94 | 926.94 | 547,374 | 05:00:06 |
From May 2023 to May 2024
By Will Feuer
Regeneron Pharmaceuticals said the Food and Drug Administration has approved an eight-milligram injection of its Eylea treatment for various eye diseases.
The dose of Eylea is approved for the treatment of wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy, Regeneron said. The two-milligram dose of Eylea is already approved by the FDA.
Regeneron is jointly developing Eylea HD with Bayer. In the U.S., Regeneron has exclusive rights to both Eylea and Eylea HD. Bayer has licensed the exclusive marketing rights outside of the U.S., where the companies share equally the profits from sales following any regulatory approvals.
Shares of Regeneron rose 0.7% in after-hours trading.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
August 18, 2023 19:24 ET (23:24 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
